nu6102 has been researched along with cyc 202 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M | 1 |
| Jarhad, DB; Jeong, LS; Kim, HR; Mashelkar, KK; Noh, M | 1 |
| Cheng, W; Kan, Q; Li, Y; Tian, X; Wang, S; Wei, H; Yang, Z | 1 |
| Edwards, DP; Moore, NL; Weigel, NL | 1 |
2 review(s) available for nu6102 and cyc 202
| Article | Year |
|---|---|
Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.
Topics: Animals; Biological Products; Disease; Dyrk Kinases; Enzyme Activation; Humans; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases | 2018 |
Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures.
Topics: Animals; Crystallography, X-Ray; Cyclin-Dependent Kinases; Humans; Molecular Structure; Protein Binding; Protein Kinase Inhibitors | 2019 |
2 other study(ies) available for nu6102 and cyc 202
| Article | Year |
|---|---|
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2007 |
Cyclin A2 and its associated kinase activity are required for optimal induction of progesterone receptor target genes in breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cyclin A2; Cyclin-Dependent Kinase 2; Female; Humans; Purines; Receptors, Progesterone; RNA, Messenger; Roscovitine | 2014 |